BIIB
Biogen Inc
NASDAQ: BIIB · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$194.38
+6.00% today
Updated 2026-04-29
Market cap
$28.53B
P/E ratio
20.92
P/S ratio
2.88x
EPS (TTM)
$9.29
Dividend yield
—
52W range
$115 – $202
Volume
1.1M
WallStSmart proprietary scores
55
out of 100
Grade: C+
Hold
Investment rating
4.0
Growth
C6.3
Quality
B6.0
Profitability
B6.0
Valuation
B2/9
Piotroski F-Score
Weak
2.5
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$212.51
+9.33%
12-Month target
$189.56
-2.48%
Intrinsic (DCF)
$355.76
Margin of safety
+46.26%
1 Strong Buy14 Buy20 Hold1 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $468.00M — positive
+ 46.26% below intrinsic value
Risks
- Piotroski 2/9 — weak financial health
- Revenue declining -7.10% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $10.17B | $9.84B | $9.68B | $9.81B | $9.89B | $9.6B |
| Net income | $3.05B | $1.16B | $1.63B | $1.29B | $-48.41M | — |
| EPS | — | — | — | — | $9.29 | $16.08 |
| Free cash flow | $1.14B | $1.24B | $2.52B | $2.05B | $468.00M | — |
| Profit margin | 29.95% | 11.81% | 16.87% | 13.18% | 13.10% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | GODBOUT, SEAN | Sale | 181 | — |
| 2026-04-01 | GODBOUT, SEAN | Buy | 181 | — |
| 2026-04-01 | GODBOUT, SEAN | Sale | 54 | $183.78 |
Peer comparison
Smart narrative
Biogen Inc trades at $194.38. representing a P/E of 20.92x trailing earnings. Our Smart Value Score of 55/100 indicates the stock is fair. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.53, it sits in the grey zone. TTM revenue stands at $9.89B. with profit margins at 13.10%. Our DCF model estimates intrinsic value at $355.76.
Frequently asked questions
What is Biogen Inc's stock price?
Biogen Inc (BIIB) trades at $194.38.
Is Biogen Inc overvalued?
Smart Value Score 55/100 (Grade C+, Hold). DCF value $355.76.
What is the price target of Biogen Inc (BIIB)?
The analyst target price is $212.51, representing +9.3% upside from the current price of $194.38.
What is the intrinsic value of Biogen Inc (BIIB)?
Based on our DCF model, intrinsic value is $355.76, a +46.3% margin of safety versus $194.38.
What is the future stock price of BIIB by 2030?
Our research-backed model estimates Biogen Inc could reach $1,134.98 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is Biogen Inc's revenue?
TTM revenue is $9.89B.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
2.53 — grey zone.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.88x
ROE7.39%
Beta0.16
50D MA$184.91
200D MA$163.84
Shares out0.15B
Float0.15B
Short ratio—
Avg volume1.1M
Performance
1 week+5.42%
1 month+5.77%
3 months+8.05%
YTD+10.45%
1 year—
3 years—
5 years—